TABLE ES-1 Recommended Finance Levels for the National Immunization System (Section 317, Vaccines for Children [VFC] Program, and state-level contributions) ($ in millions)
	Funding Source Baseline Annual Avg.a (FY 1994–1999) FY 2000 Awarda IOM Committee Recommendation Rationale for FY 2002 Appropriations FY 2002 Appropriation FEDERAL A. Section 317           1. Vaccine purchase awards 160 162 1. Sustain current spending levels to meet residual needs 160   Expenditures (child) 115 N/A         Expenditures (adult) 4 N/A 2. Increase federal assistance to the states to purchase adult vaccines to improve coverage rates 50 2. Infrastructure awards 271b 123 3. Increase annual award to reflect state capacity as reflected in historical expenditure levels 200   Expenditures 187 111 4. Increase allocation of federal funds to states that have significant immunization needs           5. Maintain a "hold harmless" condition for existing state awards     Total Section 317 Awards 431 285     410 B. VFC (vaccine purchase and operations) 397 548     548c   Total Federal Contribution (excluding Medicaid, Medicare) 828 833     958 STATE 1. Vaccine purchase estimates N/A 109d 6. Sustain and increase state vaccine purchases, especially for adults 120 2. Infrastructure funds and program operations estimates N/A 231 7. Build support for infrastructure within each state 331         8. Add state match requirement for new federal funds     Total State Contribution N/A 340     451 TOTAL (federal/state combined) Unknown 1,173     1,409
a Source: Centers for Disease Control and Prevention (CDC), National Immunization Program. State-level data based on self-reports by the states submitted to CDC in August 1999, estimating state-level expenditures for the year 2000. b Includes $261 million in Financial Assistance and $10 million in Direct Assistance; also includes carryover funds as well as new awards. c This figure is likely to increase when new recommendations of the Advisory Committee on Immunization Practices are incorporated into the vaccine schedule. For example, the pneumococcal conjugate vaccine was approved in February 2000 for all infants < 2 years of age and for high-risk children < 5 years of age. d State report data include funds from multiple sources, including state revenues and in-kind support, local funds, other federal funds applied to immunization efforts (e.g., Title V, Preventive Health Services Block Grants), and private funds.